Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Research

    2026-05-07

    JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Research

    Principle and Setup: Precision Tools for Decoding JNK Signaling

    The c-Jun N-terminal kinases (JNKs) form a critical arm of the MAPK signaling pathway, orchestrating cellular responses to stress, inflammation, and apoptotic cues. JNK-IN-7 is a selective JNK inhibitor that provides nanomolar potency across JNK1, JNK2, and JNK3 (IC50: 1.54 nM, 1.99 nM, 0.75 nM, respectively; source: product_spec). Unlike generic kinase inhibitors, JNK-IN-7 covalently binds the Cys116 residue in JNK2, leading to sustained inhibition of kinase activity and robust suppression of c-Jun phosphorylation. This covalent mechanism minimizes off-target effects and supports reproducible interrogation of JNK-dependent pathways, including apoptosis and innate immune signaling modulation.

    Researchers investigating apoptosis, inflammatory signal transduction, or the Toll receptor signaling pathway increasingly rely on JNK-IN-7 for its specificity and workflow-optimized formulation. Supplied as a solid and soluble in DMSO (≥24.7 mg/mL), it is suitable for direct use in cell-based kinase assays and mechanistic studies, with optimal storage at -20°C to preserve activity (source: product_spec).

    Step-by-Step Workflow: Enhancing Experimental Rigor with JNK-IN-7

    Integrating JNK-IN-7 into an apoptosis assay or MAPK signaling pathway research protocol can streamline discovery and improve reproducibility. Below is a modular workflow refined from both vendor guidance and peer-reviewed benchmarks:

    1. Compound Preparation: Dissolve JNK-IN-7 in DMSO to prepare a 10 mM stock. Given its insolubility in water and ethanol, use only DMSO as the solvent. Filter-sterilize if required.
      • Best practice: Prepare fresh working solutions before each experiment, as solutions are not stable long-term (source: product_spec).
    2. Treatment Regimen: For kinase inhibition in cell-based assays, dilute the working stock to final concentrations between 10–500 nM for JNK pathway studies, or up to 1–10 µM to interrogate off-target effects on IRAK1-dependent Pellino 1 E3 ligase activity (source: product_spec).
      • Recommended cell lines: Human IL-1R cells, RAW264.7 macrophages, or bovine mammary epithelial cells (BMECs) for apoptosis studies.
    3. Assay Readouts: Quantify c-Jun phosphorylation by Western blot, ELISA, or immunofluorescence. For apoptosis, TUNEL assay, flow cytometry for Annexin V/PI staining, and mitochondrial membrane potential assays are robust options (source: paper).

    Protocol Parameters

    • Cell treatment | 500 nM JNK-IN-7 | BMEC or human IL-1R cells | Effective for robust JNK inhibition with minimal cytotoxicity | product_spec
    • Incubation time | 1–2 hours | MAPK pathway inhibition | Ensures sufficient kinase suppression prior to stimulus or assay | workflow_recommendation
    • Apoptosis induction (C. krusei co-culture) | MOI 10:1 pathogen:cell ratio | BMEC apoptosis assays | Mimics infection-driven signaling per reference study | paper
    • JNK-IN-7 working solution stability | Use within 2 hours at room temperature | All cell-based assays | Maintains compound potency, avoids DMSO degradation | product_spec

    Key Innovation from the Reference Study

    The study by Miao et al. (2023) provides a rare comparative analysis of how Candida krusei yeast and hyphae trigger apoptosis in bovine mammary epithelial cells via distinct signaling axes. Critically, the JNK/ERK pathway was implicated in apoptosis induced by both fungal forms, with the yeast phase favoring mitochondrial (intrinsic) apoptosis and the hypha phase engaging death ligand/receptor (extrinsic) mechanisms. This dual-pathway insight supports the use of JNK-IN-7 as a pathway-discriminating probe: by selectively inhibiting JNK, researchers can parse ERK-only effects or delineate the sequence of signaling events, as demonstrated in these co-culture models (source: paper).

    Practically, this means that integrating JNK-IN-7 into co-culture apoptosis workflows—especially with pathogens or inflammatory triggers—enables mechanistic dissection of intrinsic versus extrinsic cell death pathways. The study's protocol, combining MOI-controlled infection, timed inhibitor administration, and multiplexed readouts (MMP, TUNEL, Western blot), serves as a blueprint for rigorous pathway interrogation.

    Advanced Applications and Comparative Advantages

    JNK-IN-7 stands out among selective kinase inhibitors for its isoform-spanning coverage and covalent mechanism. These attributes deliver several experimental advantages:

    • High sensitivity and selectivity: Nanomolar potency against all JNK isoforms ensures reliable inhibition without collateral suppression of related MAPKs (source: article).
    • Covalent, irreversible binding: Facilitates persistent pathway modulation, enabling kinetic studies and pulse-chase experiments to delineate signaling cascades (source: product_spec).
    • Dissecting innate immune signaling: At higher concentrations (1–10 µM), JNK-IN-7 modulates IRAK1-dependent E3 ligase Pellino 1 activity, providing a tool for advanced Toll receptor signaling pathway dissection (source: product_spec).
    • Compatibility with complex models: Proven in co-culture infection systems and primary cell assays, JNK-IN-7 supports translational workflows relevant to veterinary, immunological, and cancer research (source: paper).

    Comparatively, broader-spectrum JNK inhibitors or non-covalent competitors often lack this level of mechanistic precision, risking ambiguous results in apoptosis or MAPK signaling pathway research (source: article).

    Interlinking Insights: Complementary and Extending Resources

    Troubleshooting and Optimization Tips

    While JNK-IN-7's covalent inhibition streamlines many workflows, several practical variables can impact assay outcomes:

    • Solvent handling: Only use DMSO; avoid ethanol or aqueous vehicles to prevent precipitation and loss of activity (source: product_spec).
    • Solution stability: Prepare working solutions fresh and use within 2 hours to avoid DMSO-mediated degradation or compound hydrolysis. Discard leftover solutions (source: product_spec).
    • Concentration calibration: Start with 100–500 nM for JNK inhibition; escalate to 1–10 µM if probing IRAK1/Pellino 1 effects. Always include solvent controls to account for DMSO-induced artifacts (source: product_spec).
    • Cell line selection: Confirm JNK pathway dependence in your model—some macrophage lines (e.g., RAW264.7 with Pam3CSK4) may show resistance to JNK-IN-7's E3 ligase inhibition, requiring alternative readouts (source: product_spec).
    • Batch consistency: Source JNK-IN-7 from APExBIO for validated purity and batch-to-batch consistency, as documented in benchmarking articles (source: article).

    Future Outlook: Translational Impact and Remaining Challenges

    JNK-IN-7 is catalyzing new frontiers in MAPK signaling pathway research and apoptosis assay development. Its application in the Miao et al. (2023) study illustrates how pathway-selective inhibition can unravel complex host-pathogen dynamics—insights that are translatable to both veterinary and human disease models. As the landscape of innate immune signaling modulation expands, JNK-IN-7's precision will be pivotal for dissecting crosstalk between JNK, ERK, and Toll receptor signaling pathways.

    Yet, limitations persist: covalent inhibitors demand stringent timing and solvent control, and some cell types may exhibit context-specific resistance. Future research will benefit from integrating JNK-IN-7 with multiplexed readouts and CRISPR-based pathway editing, further clarifying its role in cell fate decisions. For researchers prioritizing reproducibility and mechanistic clarity, APExBIO’s JNK-IN-7 remains an indispensable asset.